What is a stock summary page? Click here for an overview.
Business Description
WuXi Biologics (Cayman) Inc
ISIN : US98260N1081
Share Class Description:
WXXWY: ADRCompare
Compare
Traded in other countries / regions
02269.Hong KongWXXWY.USA1FW2.Germany2269.Mexico IPO Date
2017-07-28Description
WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.17 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 0.99 | |||||
| Interest Coverage | 31.56 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 6.02 | |||||
| Beneish M-Score | -2.48 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 39.4 | |||||
| 3-Year EBITDA Growth Rate | 28.6 | |||||
| 3-Year EPS without NRI Growth Rate | 33.6 | |||||
| 3-Year Book Growth Rate | 20.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 10.52 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 17.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.26 | |||||
| 9-Day RSI | 31.8 | |||||
| 14-Day RSI | 39.72 | |||||
| 3-1 Month Momentum % | 35.49 | |||||
| 6-1 Month Momentum % | 7.52 | |||||
| 12-1 Month Momentum % | 63.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.73 | |||||
| Quick Ratio | 2.56 | |||||
| Cash Ratio | 1.24 | |||||
| Days Inventory | 58.37 | |||||
| Days Sales Outstanding | 110.87 | |||||
| Days Payable | 27.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.4 | |||||
| Shareholder Yield % | 1.48 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 40.96 | |||||
| Operating Margin % | 26.63 | |||||
| Net Margin % | 17.97 | |||||
| FCF Margin % | -1.71 | |||||
| ROE % | 8.14 | |||||
| ROA % | 5.89 | |||||
| ROIC % | 9.39 | |||||
| 3-Year ROIIC % | 9.41 | |||||
| ROC (Joel Greenblatt) % | 14.54 | |||||
| ROCE % | 10.14 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 26.92 | |||||
| Forward PE Ratio | 20 | |||||
| PE Ratio without NRI | 18.7 | |||||
| Shiller PE Ratio | 57.6 | |||||
| Price-to-Owner-Earnings | 688.08 | |||||
| PEG Ratio | 0.4 | |||||
| PS Ratio | 4.93 | |||||
| PB Ratio | 2.15 | |||||
| Price-to-Tangible-Book | 2.26 | |||||
| Price-to-Operating-Cash-Flow | 28.86 | |||||
| EV-to-EBIT | 16.88 | |||||
| EV-to-Forward-EBIT | 15.71 | |||||
| EV-to-EBITDA | 16.88 | |||||
| EV-to-Forward-EBITDA | 11.58 | |||||
| EV-to-Revenue | 4.51 | |||||
| EV-to-Forward-Revenue | 4.18 | |||||
| EV-to-FCF | -312.55 | |||||
| Price-to-GF-Value | 0.23 | |||||
| Price-to-Projected-FCF | 11.52 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.81 | |||||
| Price-to-Graham-Number | 1.4 | |||||
| Price-to-Net-Current-Asset-Value | 10.67 | |||||
| Earnings Yield (Greenblatt) % | 5.92 | |||||
| FCF Yield % | -0.37 | |||||
| Forward Rate of Return (Yacktman) % | 18.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:WXXWY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
WuXi Biologics (Cayman) Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2,569.272 | ||
| EPS (TTM) ($) | 0.214 | ||
| Beta | -0.42 | ||
| 3-Year Sharpe Ratio | -0.14 | ||
| 3-Year Sortino Ratio | -0.22 | ||
| Volatility % | 68.93 | ||
| 14-Day RSI | 39.72 | ||
| 14-Day ATR ($) | 0.316071 | ||
| 20-Day SMA ($) | 6.61894 | ||
| 12-1 Month Momentum % | 63.69 | ||
| 52-Week Range ($) | 2.58 - 7.3 | ||
| Shares Outstanding (Mil) | 2,048.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
WuXi Biologics (Cayman) Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
WuXi Biologics (Cayman) Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
WuXi Biologics (Cayman) Inc Frequently Asked Questions
What is WuXi Biologics (Cayman) Inc(WXXWY)'s stock price today?
The current price of WXXWY is $5.76. The 52 week high of WXXWY is $7.30 and 52 week low is $2.58.
When is next earnings date of WuXi Biologics (Cayman) Inc(WXXWY)?
The next earnings date of WuXi Biologics (Cayman) Inc(WXXWY) is 2025-08-21 Est..
Does WuXi Biologics (Cayman) Inc(WXXWY) pay dividends? If so, how much?
WuXi Biologics (Cayman) Inc(WXXWY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers